For instance, Brilliant Blue G (P2X7 antagonists) inhibit sNLRP3 inflammasomes and slows ALS progression in clinical trials, while 2-MeSADP (P2Y12 agonists) enhance microglial ramification and BDNF release in stroke models [160,163,164]. This evidence concerns the gene BDNF and amyotrophic lateral sclerosis.